SDI Collaborates with Fred Hutchinson Cancer Research Center to Discover Cancer Biomarkers
News Jan 07, 2010
SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) have jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers. Initial studies will center on pancreatic cancer.
“We are excited about the opportunity to explore SDI’s proprietary Genomic Antibody Technology™ through access to its Cancer Antigen Antibody Collection with the hope of identifying novel cancer biomarkers that will advance the prognostic and diagnostic potential for these challenging diseases”
SDI will provide the Hutchinson Center with approximately 1,000 antibodies for the collaborative studies from its unique collection of cancer antigen antibodies. The antibodies, which were designed using SDI’s proprietary Genomic Antibody Technology™, will be provided to Paul Lampe, Ph.D., full member and associate program head of the Molecular Diagnostics Program at the Hutchinson Center.
The SDI cancer antigen antibodies will be printed by the Lampe laboratory onto microarray slides and tested against up to 200 characterized patient case samples and controls in a first discovery screening assay. Upon completion, the Hutchinson Center and SDI plan to jointly publish the biomarker findings of these studies. SDI will have an option for the Hutchinson Center’s commercial rights to any work that is developed during the agreement.
A biomarker is a biological molecule that can be found in body fluids such as blood or in tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may also be used to see how well the body responds to a treatment for a disease or condition. It can also be called a molecular marker or a signature molecule.
“We are excited about the opportunity to explore SDI’s proprietary Genomic Antibody Technology™ through access to its Cancer Antigen Antibody Collection with the hope of identifying novel cancer biomarkers that will advance the prognostic and diagnostic potential for these challenging diseases,” Lampe said.
The Lampe laboratory investigates the control of cell growth both at the cell biological/mechanistic level and through cancer biomarker discovery. Lampe and colleagues study the cell biology that connects gap junctions and intercellular communication (GJIC) with the control of cell growth and the cell cycle and how this relationship is disrupted during carcinogenesis.
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Eating Activates Calorie-Burning FatNews
The importance of the human brown adipose tissue (BAT) has become clearer during the past ten years. Coldness is one of the most effective activators of the BAT metabolic function but, in rodents, eating has also been shown to activate BAT. The debate on whether eating has the same effect on humans has lasted for decades. Now, the researchers at Turku PET Centre have proven that having a meal increases oxygen consumption in human BAT to the same extent as coldness.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018